about
Vegetarian Diet in Chronic Kidney Disease-A Friend or Foe.The Effect of Diet on the Survival of Patients with Chronic Kidney Disease.Personalized Medicine: New Perspectives for the Diagnosis and the Treatment of Renal DiseasesMarkers of increased cardiovascular risk in patients with chronic kidney disease.The multi-biomarker approach for heart failure in patients with hypertension.Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study.Molecular mechanisms of statin intoleranceFibroblast growth factor 19-targeted therapies for the treatment of metabolic disease.Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge.Sudden cardiac death in CKD patients.Novel Biomarkers in the Diagnosis of Chronic Kidney Disease and the Prediction of Its Outcome.Lipid-modifying effects of nutraceuticals: An evidence-based approach.Efficacy of Statin Therapy in Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.Combination drug versus monotherapy for the treatment of autosomal dominant polycystic kidney disease.Hypertension - Current Natural Strategies to Lower Blood Pressure.The Use of Plant Sterols and Stanols as Lipid-Lowering Agents in Cardiovascular Disease.Relationship between long noncoding RNAs and physiological risk factors of cardiovascular disease.Assessment of the relationship between selected cardiovascular risk factors and the indices of intima-media thickness and coronary artery calcium score in various stages of chronic kidney disease.The role and function of HDL in patients with diabetes mellitus and the related cardiovascular risk.The sirtuin family members SIRT1, SIRT3 and SIRT6: Their role in vascular biology and atherogenesis.Biomarkers of cardiovascular risk in haemodialysis patients.The Problem of Atrial Fibrillation in Patients with Chronic Kidney Disease.Do HDL and LDL subfractions play a role in atherosclerosis in end-stage renal disease (ESRD) patients?Lipoprotein Subfractions, Uric Acid and Cardiovascular Risk in End-Stage Renal Disease (ESRD) Patients.High-Density Lipoprotein and Low-Density Lipoprotein Subfractions in Patients with Chronic Kidney Disease.The occurrence of atrial fibrillation in dialysis patients and its association with left atrium volume before and after dialysis.Impact of Vitamin D on the Cardiovascular System in Advanced Chronic Kidney Disease (CKD) and Dialysis Patients.Embracing the polypill as a cardiovascular therapeutic: is this the best strategy?Are Markers of Cardiac Dysfunction Useful in the Assessment of Cardiovascular Risk in Dialysis Patients?Cholesterol Disturbances and the Role of Proper Nutrition in CKD PatientsThe Role and Function of HDL in Patients with Chronic Kidney Disease and the Risk of Cardiovascular DiseaseThe Influence of Inflammation on Anemia in CKD PatientsBiochemical markers in the prediction of contrast-induced acute kidney injurySerum NGAL, KIM-1, IL-18, L-FABP: new biomarkers in the diagnostics of acute kidney injury (AKI) following invasive cardiology procedures
P50
Q33616816-647C72DD-B249-40C6-A048-F7FF1C58D4E2Q33749490-9A91F64B-1ACC-46DD-91B8-BA79A2637E38Q33838866-201D7BE9-2507-4A98-8E05-DEBBE6B930AAQ34582124-F42C92F9-4BE2-44AA-B033-134A9A895902Q35723466-011D2C6E-D8B3-45E1-820E-FC5D9B712FBDQ36538088-6F45722F-483E-4001-AB0B-2AB8E4290010Q36958324-AC7367B9-4832-46DA-A72D-2E46A874B052Q38325739-B69C910E-22B7-425A-9E0F-417FAEAD78C6Q38372669-718C387F-9D84-419A-8F70-E9A8F74EBFD1Q38473007-022B54D6-46C8-499B-9827-A8473E3FC4C1Q38646836-B7B3945B-4B06-4634-8F2E-50C582F7487EQ38870916-20047190-1ACA-49F4-A30D-66E1B0B11C58Q38904855-DFECA2F7-28A9-4A99-89C5-B66DFA21D491Q38960067-0C66A673-168E-46AE-A32A-362341A644CFQ39142446-7B6AAB2C-B409-4D54-8387-0E6A5BFC891EQ39182448-FA7D7E0A-06C9-41EC-AB19-0B54AC545DC8Q39255411-EB047E2C-E07C-4817-94EF-5EE775904EA9Q41192280-3B5E54DD-16ED-43A0-AB97-B10042F4B0BFQ44819479-30817526-2BEB-46B7-B430-E630CD19ECC8Q47858886-510BD5EE-6DB9-4DAD-9F5E-DAAC46C8A9CDQ47944999-69EBDC9D-263D-4CE5-B8D7-EA36130D0CCEQ48883042-63AFF26E-30DA-4ACE-B3ED-CDA40BA3A945Q51273079-DD1BB899-F0D4-49B7-8799-87FEBB0E0D41Q51367188-4B82BF8D-D5FC-4286-A5E1-63C13E29F424Q51437231-66907FA8-18AD-4655-9BB5-F33882FB8004Q52901309-0C737B72-A019-4413-BF8E-4C81CCAE6C9FQ55515176-51CA0F02-5C83-4519-B5A9-B9F6E2F49D7CQ59683743-ADC28FC3-441B-429A-9A6C-FD187F52CB2BQ59683920-D129B3D8-8FC2-409E-B4A1-626CF4FD1BD2Q91377155-23DC3D2C-602E-405A-A3E9-CB5782280337Q92811508-86660349-8198-4FF4-B9CB-06E7945B806CQ92921916-B53BC2EB-7A17-4702-8B2C-3B5F567BB4C8Q94481717-BD253462-0F60-4F1D-A1C7-33893349BF97Q96583532-5FCAA498-5435-47FC-B48C-CE75EC746685
P50
description
researcher ORCID ID = 0000-0003-3322-5655
@en
wetenschapper
@nl
name
Anna Gluba-Brzózka
@ast
Anna Gluba-Brzózka
@en
Anna Gluba-Brzózka
@es
Anna Gluba-Brzózka
@nl
type
label
Anna Gluba-Brzózka
@ast
Anna Gluba-Brzózka
@en
Anna Gluba-Brzózka
@es
Anna Gluba-Brzózka
@nl
prefLabel
Anna Gluba-Brzózka
@ast
Anna Gluba-Brzózka
@en
Anna Gluba-Brzózka
@es
Anna Gluba-Brzózka
@nl
P1153
56386089100
8419128800
P21
P31
P496
0000-0003-3322-5655